Receive our newsletter – data, insights and analysis delivered to you
  1. News
June 30, 2021

4G Clinical to obtain $230m growth equity investment

The company has so far supported clinical trials for nearly 100 biotech and pharma customers.

Randomisation and trial supply management (RTSM) software specialist 4G Clinical has signed an agreement to secure a growth equity investment exceeding $230m from Goldman Sachs Asset Management.

The company will use the proceeds to continue its international expansion and meet the rising demand for its products. The funds will also support 4G Clinical’s aim to expedite access to critical drugs.

Established in 2015, 4G Clinical uses natural language processing (NLP) to transform the execution of clinical trials, subsequently fast-tracking the studies.

The company’s Prancer RTSM allows life sciences companies to attain the first patient in (FPI) up to 50% quicker compared with other providers, as well as efficiently deploy mid-trial changes.

4C Supply, the company’s clinical supply optimisation solution, integrates real-time RTSM actuals to avoid stock-outs and reduced drug waste.

4G Clinical CEO David Kelleher said: “In just over five years, 4G Clinical has grown from a start-up to a globally recognised leader in RTSM, helping life sciences organisations execute clinical trials of any size and complexity throughout the drug development lifecycle.

Content from our partners
Africa’s last mile: Building viable vaccine supply chains
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide

“To maximise our impact on lives around the globe, we must unwaveringly drive innovation in our technology and processes to tackle clinical trial bottlenecks. This investment from Goldman Sachs ensures that we will not be constrained in any way in that effort.”

Among life sciences companies, the use of eClinical solutions such as Prancer RTSM and 4C Supply is increasing to address the growing complexity of trials, 4G Clinical noted.

4G Clinical has currently supported trials for more than 100 biotech and pharma clients worldwide.

Goldman Sachs Asset Management managing director Jason Kreuziger said: “The eClinical Solutions market has expanded rapidly over the past several years with best-in-class, tech-first solutions leading the way, presenting an exciting opportunity for Goldman Sachs.

“4G Clinical’s established reputation and global reach to date underscore their immense potential over the next few years.”

Headquartered in Wellesley, Massachusetts, US, 4G Clinical also has offices in Europe and Asia.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU